StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS – Free Report) in a research report report published on Saturday morning. The brokerage issued a strong-buy rating on the stock.
FMS has been the subject of several other research reports. Berenberg Bank started coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price target for the company. Truist Financial upped their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Fresenius Medical Care has a consensus rating of “Moderate Buy” and a consensus price target of $24.30.
View Our Latest Analysis on FMS
Fresenius Medical Care Trading Down 0.8 %
Hedge Funds Weigh In On Fresenius Medical Care
A number of hedge funds and other institutional investors have recently bought and sold shares of FMS. Allworth Financial LP lifted its stake in shares of Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after acquiring an additional 581 shares during the period. GAMMA Investing LLC lifted its position in Fresenius Medical Care by 50.4% in the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after purchasing an additional 1,675 shares during the period. ORG Wealth Partners LLC acquired a new stake in Fresenius Medical Care in the third quarter valued at about $112,000. Venturi Wealth Management LLC boosted its holdings in Fresenius Medical Care by 1,045.8% in the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock valued at $112,000 after purchasing an additional 4,800 shares in the last quarter. Finally, SageView Advisory Group LLC acquired a new position in Fresenius Medical Care during the 1st quarter worth approximately $127,000. 8.25% of the stock is currently owned by hedge funds and other institutional investors.
Fresenius Medical Care Company Profile
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
See Also
- Five stocks we like better than Fresenius Medical Care
- Where Do I Find 52-Week Highs and Lows?
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.